{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T11:21:44Z","timestamp":1788002504959,"version":"build-2784847793"},"reference-count":91,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"German Cancer Aid\u2014Max Eder","doi-asserted-by":"publisher","award":["108879"],"award-info":[{"award-number":["108879"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid\u2014Max Eder","doi-asserted-by":"publisher","award":["SFB824 Project C7"],"award-info":[{"award-number":["SFB824 Project C7"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid\u2014Max Eder","doi-asserted-by":"publisher","award":["8810004260"],"award-info":[{"award-number":["8810004260"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation (DFG)","doi-asserted-by":"publisher","award":["108879"],"award-info":[{"award-number":["108879"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation (DFG)","doi-asserted-by":"publisher","award":["SFB824 Project C7"],"award-info":[{"award-number":["SFB824 Project C7"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation (DFG)","doi-asserted-by":"publisher","award":["8810004260"],"award-info":[{"award-number":["8810004260"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>As the mechanisms underlying tumorigenesis become better understood, the dynamic roles of cellular components of the tumor microenvironment, and their cross-talk with tumor cells, have come to light as key drivers of disease progression and have emerged as important targets of new cancer therapies. In the field of oncolytic virus (OV) therapy, stromal cells have been considered as potential barriers to viral spread, thus limiting virus replication and therapeutic outcome. However, new evidence indicates that intratumoral fibroblasts could support virus replication. We have demonstrated in a rat model of stromal-rich intrahepatic cholangiocarcinoma (CCA) that vesicular stomatitis virus (VSV) can be localized within intratumoral hepatic stellate cells (HSCs), in addition to tumor cells, when the virus was applied via hepatic arterial infusion. Furthermore, VSV was shown to efficiently kill CCA cells and activated HSCs, and co-culture of CCA and HSCs increased viral titers. Interestingly, this effect is also observed when each cell type is cultured alone in a conditioned medium of the other cell type, indicating that secreted cell factors are at least partially responsible for this phenomenon. Partial reduction in sensitivity to type I interferons was observed in co-culture systems, providing a possible mechanism for the increased viral titers. Together, the results indicate that targeting activated HSCs with VSV could provide an additional mechanism of OV therapy, which, until now has not been considered. Furthermore, these findings suggest that VSV is a potentially powerful therapeutic agent for stromal-rich tumors, such as CCA and pancreatic cancer, both of which are very difficult to treat with conventional therapy and have a very poor prognosis.<\/jats:p>","DOI":"10.3390\/cancers17030514","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:13:43Z","timestamp":1738646023000},"page":"514","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cross-Talk Between Tumor Cells and Stellate Cells Promotes Oncolytic VSV Activity in Intrahepatic Cholangiocarcinoma"],"prefix":"10.3390","volume":"17","author":[{"given":"Victoria","family":"Neumeyer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 2, University Hospital of the Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva","family":"Chavan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, University Hospital of the Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7269-5433","authenticated-orcid":false,"given":"Katja","family":"Steiger","sequence":"additional","affiliation":[{"name":"Department of Pathology, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ebert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, University Hospital of the Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1079-3633","authenticated-orcid":false,"given":"Jennifer","family":"Altomonte","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, University Hospital of the Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mds652","article-title":"A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe","volume":"24","author":"Bertuccio","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2003.11.030","article-title":"Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase?","volume":"40","author":"Shaib","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: Current Knowledge and New Developments","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut Liver"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1634\/theoncologist.9-1-43","article-title":"Diagnosis and treatment of cholangiocarcinoma","volume":"9","author":"Anderson","year":"2004","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0168-8278(96)80267-4","article-title":"Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas","volume":"24","author":"Terada","year":"1996","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MOG.0b013e32834405c3","article-title":"Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma","volume":"27","author":"Sirica","year":"2011","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kinzler, M.N., Klasen, C., Schulze, F., Herrmann, E., Schnitzbauer, A.A., Trojan, J., Zeuzem, S., Wild, P.J., and Walter, D. (2022). Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy. J. Clin. Med., 11.","DOI":"10.3390\/jcm11072057"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hep.26053","article-title":"A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice","volume":"57","author":"Puche","year":"2013","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1038\/ncomms3823","article-title":"Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology","volume":"4","author":"Mederacke","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1245\/s10434-010-1391-7","article-title":"Hepatic stellate cells accelerate the malignant behavior of cholangiocarcinoma cells","volume":"18","author":"Okabe","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/hep.26762","article-title":"Desmoplastic stroma and cholangiocarcinoma: Clinical implications and therapeutic targeting","volume":"59","author":"Sirica","year":"2014","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1245\/s10434-009-0568-4","article-title":"Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma","volume":"16","author":"Okabe","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1245\/s10434-014-3531-y","article-title":"Hedgehog signaling between cancer cells and hepatic stellate cells in promoting cholangiocarcinoma","volume":"21","author":"Kim","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_15","first-page":"957","article-title":"Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma","volume":"21","author":"Chuaysri","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Baglieri, J., Brenner, D.A., and Kisseleva, T. (2019). The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071723"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/labinvest.2013.139","article-title":"Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model","volume":"94","author":"Zhao","year":"2014","journal-title":"Lab. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1038\/s41388-021-01705-9","article-title":"Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2\/osteopontin\/Wnt signaling axis","volume":"40","author":"Jing","year":"2021","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41575-019-0115-0","article-title":"Cancer-associated fibroblasts in gastrointestinal cancer","volume":"16","author":"Kobayashi","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2015.11.011","article-title":"Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche","volume":"64","author":"Govaere","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, P.W., Lin, T.Y., Yang, P.M., Yeh, C.T., and Pan, T.L. (2022). Hepatic Stellate Cell Modulates the Immune Microenvironment in the Progression of Hepatocellular Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810777"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canlet.2021.08.002","article-title":"The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-beta in CAF mediated tumor progression and therapeutic resistance","volume":"520","author":"Sarkar","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chung, J.Y., Chan, M.K., Li, J.S., Chan, A.S., Tang, P.C., Leung, K.T., To, K.F., Lan, H.Y., and Tang, P.M. (2021). TGF-beta Signaling: From Tissue Fibrosis to Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147575"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Stuelten, C.H., and Zhang, Y.E. (2021). Transforming Growth Factor-beta: An Agent of Change in the Tumor Microenvironment. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.764727"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/hep.26577","article-title":"Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma","volume":"58","author":"Sulpice","year":"2013","journal-title":"Hepatology"},{"key":"ref_26","first-page":"3605","article-title":"Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats","volume":"63","author":"Ebert","year":"2003","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ymthe.2003.12.004","article-title":"Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus","volume":"9","author":"Shinozaki","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hep.20536","article-title":"Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV","volume":"41","author":"Shinozaki","year":"2005","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kimpel, J., Urbiola, C., Koske, I., Tober, R., Banki, Z., Wollmann, G., and von Laer, D. (2018). The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma. Viruses, 10.","DOI":"10.3390\/v10030108"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10283","DOI":"10.1128\/JVI.01412-13","article-title":"Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma","volume":"87","author":"Hastie","year":"2013","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/mt.2013.181","article-title":"Antifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis","volume":"21","author":"Altomonte","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10495-005-1055-4","article-title":"The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis","volume":"10","author":"Elsharkawy","year":"2005","journal-title":"Apoptosis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1111\/j.1440-1746.2006.04658.x","article-title":"Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis","volume":"22","author":"Kisseleva","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1478-3231.2009.01971.x","article-title":"Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice","volume":"29","author":"Li","year":"2009","journal-title":"Liver Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nm.3848","article-title":"Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity","volume":"21","author":"Ilkow","year":"2015","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.trecan.2018.01.007","article-title":"Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma","volume":"4","author":"Hogdall","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","author":"Sahai","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2217\/fon-2020-0299","article-title":"Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions\/translocations: The PROOF 301 trial","volume":"16","author":"Makawita","year":"2020","journal-title":"Future Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/17474124.2021.1853527","article-title":"Recent advances of immunotherapy for biliary tract cancer","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Krenzien, F., Nevermann, N., Krombholz, A., Benzing, C., Haber, P., Fehrenbach, U., Lurje, G., Pelzer, U., Pratschke, J., and Schmelzle, M. (2022). Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach. Cancers, 14.","DOI":"10.3390\/cancers14020362"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1517\/14712590903170653","article-title":"Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways","volume":"9","author":"Naik","year":"2009","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat. Med."},{"key":"ref_48","first-page":"381","article-title":"Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma","volume":"143","author":"Dalal","year":"1993","journal-title":"Am. J. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ng1001-117","article-title":"TGF-beta signaling in tumor suppression and cancer progression","volume":"29","author":"Derynck","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Sukowati, C.H., Anfuso, B., Croce, L.S., and Tiribelli, C. (2015). The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1196-y"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/jhbp.125","article-title":"Tumor necrosis factor-\u03b1 modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression","volume":"21","author":"Techasen","year":"2014","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Chen, Y., Ma, L., He, Q., Zhang, S., Zhang, C., and Jia, W. (2015). TGF-beta1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. Biol. Res., 48.","DOI":"10.1186\/s40659-015-0016-9"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2353\/ajpath.2010.090747","article-title":"Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor-\u03b21\/Snail Activation Aggravates Invasive Growth of Cholangiocarcinoma","volume":"177","author":"Sato","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wang, H., Li, C., Jian, Z., Ou, Y., and Ou, J. (2015). TGF-beta1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0136703"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.canlet.2016.05.038","article-title":"Expression of transforming growth factor beta1 promotes cholangiocarcinoma development and progression","volume":"380","author":"Huang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","article-title":"TGF-beta in progression of liver disease","volume":"347","author":"Dooley","year":"2012","journal-title":"Cell Tissue Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.cgh.2009.07.038","article-title":"Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis","volume":"7","author":"Masamune","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1158\/0008-5472.CAN-08-1132","article-title":"Pancreatic stellate cells and pancreatic cancer cells: An unholy alliance","volume":"68","author":"Vonlaufen","year":"2008","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kelley, R.K., Gane, E., Assenat, E., Siebler, J., Galle, P.R., Merle, P., Hourmand, I.O., Cleverly, A., Zhao, Y., and Gueorguieva, I. (2019). A Phase 2 Study of Galunisertib (TGF-\u03b21 Receptor Type I Inhibitor) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Clin. Transl. Gastroenterol., 10.","DOI":"10.14309\/ctg.0000000000000056"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"552","DOI":"10.5534\/wjmh.190071","article-title":"Vactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie\u2019s Disease","volume":"38","author":"Song","year":"2020","journal-title":"World J. Mens. Health"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12943-015-0468-0","article-title":"Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: Implications for in vivo mode of action","volume":"14","author":"Bartscht","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Hong, E., Park, S., Ooshima, A., Hong, C.P., Park, J., Heo, J.S., Lee, S., An, H., Kang, J.M., and Park, S.H. (2020). Inhibition of TGF-\u03b2 signalling in combination with nal-IRI plus 5-Fluorouracil\/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-59893-5"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zhang, M., Zhang, Y.Y., Chen, Y., Wang, J., Wang, Q., and Lu, H. (2021). TGF-\u03b2 Signaling and Resistance to Cancer Therapy. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.786728"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1084\/jem.20151193","article-title":"Tumor macrophages are pivotal constructors of tumor collagenous matrix","volume":"213","author":"Afik","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Pan, Y., Yu, Y., Wang, X., and Zhang, T. (2020). Tumor-Associated Macrophages in Tumor Immunity. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.583084"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.1111\/febs.15726","article-title":"Tumor-associated macrophages in immunotherapy","volume":"288","author":"Yan","year":"2021","journal-title":"FEBS J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/2159-8290.CD-15-1346","article-title":"Macrophage PI3K\u03b3 drives pancreatic ductal adenocarcinoma progression","volume":"6","author":"Kaneda","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/j.1349-7006.2010.01614.x","article-title":"Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma","volume":"101","author":"Hasita","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.7314\/APJCP.2015.16.7.3043","article-title":"Quantitative changes in tumor-associated M2 Macrophages characterize cholangiocarcinoma and their association with metastasis","volume":"16","author":"Thanee","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1038\/bjc.2013.610","article-title":"Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer","volume":"109","author":"Goeppert","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/bjc.2017.401","article-title":"Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma","volume":"118","author":"Kitano","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Jiang, C., Wang, M., Yao, W., Lv, G., Liu, X., and Wang, G. (2022). Comprehensive Analysis on Prognosis and Immune Infiltration of Lysyl Oxidase Family Members in Pancreatic Adenocarcinoma with Experimental Verification. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.778857"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-019-0556-6","article-title":"Collagen density regulates the activity of tumor-infiltrating T cells","volume":"7","author":"Kuczek","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/2159-8290.CD-21-1640","article-title":"Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Kepecs","year":"2023","journal-title":"Gut"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","article-title":"Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition","volume":"27","author":"Taki","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell-cancer cycle: Advances and new challenges in NK cell-based immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Fabian, K.P., Wolfson, B., and Hodge, J.W. (2021). From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.728018"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/imr.12574","article-title":"Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses","volume":"280","author":"Garg","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Asadzadeh, Z., Safarzadeh, E., Safaei, S., Baradaran, A., Mohammadi, A., Hajiasgharzadeh, K., Derakhshani, A., Argentiero, A., Silvestris, N., and Baradaran, B. (2020). Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death. Cancers, 12.","DOI":"10.20944\/preprints202003.0228.v1"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez-Labrada, A., Pesini, C., Santiago, L., Hidalgo, S., Calvo-P\u00e9rez, A., O\u00f1ate, C., Andr\u00e9s-Tovar, A., Garz\u00f3n-Titua\u00f1a, M., Uranga-Murillo, I., and Arias, M.A. (2022). All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.896228"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/mt.2008.88","article-title":"A Critical Role for Type I IFN\u2013dependent NK Cell Activation in Innate Immune Elimination of Adenoviral Vectors In Vivo","volume":"16","author":"Zhu","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"van Vloten, J.P., Matuszewska, K., Minow, M.A.A., Minott, J.A., Santry, L.A., Pereira, M., Stegelmeier, A.A., McAusland, T.M., Klafuric, E.M., and Karimi, K. (2022). Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. J. Immunother. Cancer, 10.","DOI":"10.1136\/jitc-2021-004335"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1761229","DOI":"10.1080\/2162402X.2020.1761229","article-title":"Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition","volume":"9","author":"Quixabeira","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Glauss, S., Neumeyer, V., Hanesch, L., Marek, J., Hartmann, N., Wiedemann, G.M., and Altomonte, J. (2024). A Novel Chimeric Oncolytic Virus Mediates a Multifaceted Cellular Immune Response in a Syngeneic B16 Melanoma Model. Cancers, 16.","DOI":"10.3390\/cancers16193405"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gu, A., Li, J., Li, M.Y., and Liu, Y. (2025). Patient-derived xenograft model in cancer: Establishment and applications. MedComm, 6.","DOI":"10.1002\/mco2.70059"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"9420025","DOI":"10.26599\/FMH.2024.9420025","article-title":"Research progress of microrobots in tumor drug delivery","volume":"1","author":"Wang","year":"2024","journal-title":"Food Med. Homol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Wang, X., Mao, K., Zhang, X., Zhang, Y., Yang, Y.-G., and Sun, T. (2024). Red blood cell derived nanocarrier drug delivery system: A promising strategy for tumor therapy. Interdiscip. Med., 2.","DOI":"10.1002\/INMD.20240014"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/514\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:26:33Z","timestamp":1760027193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":91,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030514"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030514","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]}}}